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WT1-AS promotes cell apoptosis in
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down-regulating of WT1
Long Lv1*†, Gong Chen1†, Jianping Zhou2†, Jun Li3 and Jianping Gong4
Abstract
Background: The antisense of the tumor suppressor gene WT1 (WT1-AS) is a long non-coding RNA. The role of
WT1-AS in the development of hepatocellular carcinoma (HCC) has not yet been elucidated.
Methods: Quantitative real-time PCR and western blot analyses were used to measure levels of WT1-AS and its
related genes in tumor and corresponding adjacent tumor tissues of HCC patients. The effect on HCC cell proliferation
and apoptosis was assessed by EdU incorporation assays and PI-Annexin-V staining, respectively. ShRNA and dual-
luciferase assays were used to investigate the regulatory relationship between WT1-AS and WT1 in cell lines.
Results: WT1-AS expression correlated negatively with WT1 expression in HCC tumor tissue. Kaplan-Meier curve
analysis revealed that WT1-AS expression is a reliable indicator of HCC prognosis. The downregulation of WT1
expression by WT1-AS promoted cell apoptosis by suppressing the JAK/STAT3 signaling pathway. Bioinformatics
analysis showed that WT1-AS downregulates WT1 by binding to the TATA region of the WT1 promotor. WT1-AS was
also able to reverse WT1-mediated resistance to Dox based chemotherapy in HCC cells.
Conclusions: WT1-AS downregulates WT1 expression in HCC tumors and promotes apoptosis by binding to the
promoter region of WT1. Our findings suggest that WT1-AS may function as a tumor suppressor in HCC by reversing
the oncogenic effects of WT1.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most com-
mon malignant tumor and is the third leading cause of
cancer-related death worldwide [1]. There are several
approaches to treating HCC, including surgical resection,
liver transplantation, transcatheter arterial chemoemboliza-
tion and local radiofrequency ablation, but none have
improved the overall long-term survival of patients. This is
largely attributed to the high malignancy and efficient intra-
hepatic invasion of HCC tumors, which leads to frequent
reoccurrence after treatment [2, 3]. Novel biomarkers or
HCC treatments are therefore in considerable demand.
Wilms’ tumor 1 gene (WT1) is located on chromosome
11p13 [4] and regulates several genes including PDGF-A
chain, IGF-II, IGF-IR, c-myc and bcl-2 [5]. WT1 regulates
transcription, RNA metabolism, translation and both onco-
genic and tumor suppressor functions [6]. Researchers have
found that the over-expression of WT1 acted as an onco-
gene in the pathogenesis of neoplasm [7]. WT1
overexpression has now been reported in various tumors
and is predictive of a poor prognosis in breast cancer [8]. A
similar effect for WT1 has also been reported in HCC;
WT1 overexpression has been associated with poor prog-
nosis, enhanced tumor progression and resistance to
chemotherapy [9]. Moreover, overexpression of WT1 have
been investigated in human HCC, related to poor prognosis
of post-surgery patients and contributed to tumor progres-
sion and resistance to chemotherapy [10, 11], to explore a
novel therapeutic approach for HCC, we investigated the
causes of WT1 upregulation in HCC tumor tissue.
The long non-coding RNAs (lncRNAs) are important
for predicting survival and metastasis in liver cancer
[12]. LncRNAs regulate the progression of liver disease
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by a variety of mechanisms including DNA imprinting,
X inactivation, DNA demethylation, gene transcription
and RNA synthesis [13]. Furthermore, several reports
have demonstrated that lncRNAs are subjected to epigen-
etic modifications, including methylation, ubiquitination
and miRNA-induced regulation [14].
Materials and methods
Patient samples
Study data were obtained from 90 patients who presented
between September 2012 and October 2013 at The First
Affiliated Hospital of Nanjing Medical University (Nanjing,
China). Informed consent for tissue analysis was obtained
prior to surgery; the study was approved by our Institu-
tional Ethics Committee. All research was performed in
compliance with government policies and the Helsinki Dec-
laration. Experiments were undertaken with the under-
standing and written consent of each subject. The clinical
information was analyzed in Table 1.
Quantitative RT-PCR
Quantitative real time polymerase chain reaction (qRT-PCR)
was performed to determine the expression levels of WT1-
AS of all related genes. Total RNA was obtained from tissues
using TRIzol reagent as described by the manufacturer
(Invitrogen Life Technologies Co, CA, USA). For mRNA
detection, total RNAs (500 ng) were reverse transcribed
using the reverse transcription kit (Takara, Tokyo, Japan) at
37 °C for 15 min and 85 °C for 30 s. QRT-PCR was per-
formed using ABI Prism 7900HT (Applied Biosystems, CA,
USA). β-actin was used as an internal control. PCR was
performed for 5 s at 95 °C and for 30 s at 60 °C for
40 cycles. The detailed sequence information was pre-
sented in additional file 1 online.
Protein analysis
For Western-blots, total proteins were extracted from
tissues or cultured cells using RIPA buffer containing
protease inhibitors cOmplete, ULTRA, Mini, EDTA-free,
EASYpack (Roche, Basel, Switzerland), while the mem-
brane proteins were extracted from tissues by Mem-PER
Eukaryotic Membrane Protein Extraction Reagent Kit
(Thermo Scientific, Rockford, USA). Protein concentra-
tions were determined by the BCA method. Equal
amount of proteins (100ug) were separated with 7.5 %/
12.5 % sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to PVDF mem-
brane. Membrane was blocked using 5 % skimmed milk
and incubated with respective antibodies. Primary poly-
clonal antibodies were purchased from Santa Cruz Bio-
technology (CA, USA) and Abcam (CA, USA) including
WT1 (ab96792), p-STAT3 (ab30647), STAT3 (ab68153),
p-MAPK (ab63378), MAPK (ab197348), GAPDH (sc-
48166), β-actin (sc-47778), Caspase 3 (ab2302), MDR1
(sc-13131). The secondary antibodies were anti-rabbit or
anti-mouse HRP-linked were purchased from Santa
Cruz Biotechnology (CA, USA). The blots were devel-
oped using ECL reagent (Millpore, MASS, USA). Equal
amount of protein loading in each lane was confirmed
using GAPDH antibody. All experiments were repeated
at least three times.
Cell culture and reagents
Human HCC cell lines were obtained from American
Type Culture Collection (ATCC, Manassas VA, USA),
which were cultured in complete growth medium DMEM
(Hyclone, UT, USA), supplemented with 10 % fetal bovine
serum (10 % FBS), 100 U/mL penicillin, and 100 μg/mL
streptomycin at 37 °C, 5 % CO2 Cells were cultured to
about 50 % confluence and transfection was carried out
using Lipofectamine 2000 (Invitrogen Corp, CA, USA).
Cell apoptosis and proliferation assay
For the apoptosis analysis, cells were washed in PBS,
and then processed with Annexin V-FITC Apoptosis
Detection Kit (BD Biopharmingen, NJ, and USA) for
15 min in the dark. All experiments were analyzed by
BD Biasciences FACS Calibur Flow Cytometry (BD
Biasciences, NJ, and USA). The tests were repeated for
three times with triplicate per experiment. Cell proliferation
was assayed by using EDU (5-ethynyl-2′-deoxyuridine).
(Roche, Basel, Switzerland) as described previously [15].
Fluorescent In Situ Hybridization (FISH)
Cells were briefly rinsed in PBS and fixed in 4 % formal-
dehyde in PBS (pH 7.4) for 15 min at room temperature.
Table 1 Correlation between expression level of WT1-AS and
clinical characteristic of patients
WT1-AS
Character Low High P value
45 45
Age
< 60 30 28 >0.05




Tumor Size (cm) <0.05
≤ 5 cm 17 27




TNM stage (I:II:III) 19:16:10 20:15:10 >0.05
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Then the cells were permeabilized in PBS containing
0.5 % Triton X-100 on ice for 10 min; washed with PBS
and rinsed once in 2 × SSC prior to hybridization. Using
an anti-WT1-AS oligodeoxynucleotide probe which was
conjugated with Alexa Fluor 488 (Invitrogen, Carlsbad,
CA), hybridization was performed in hybridization solu-
tion (probe dilution 1:1250) (Boster, China) for 16 h at
50 °C in a moist chamber. For FISH, cells were washed
for 30 min in 25 % deionized formamide/2 × SSC at
50 °C and then at 50 °C, 30 min in 2 × SSC.
Dual-luciferase reporter assay
The promoter sequence of WT1 predicted to interact
with WT1-AS or a mutated sequence with the predicted
target sites were inserted into the KpnI and SacI sites of
pGL3 promoter vector (Genscript, Nanjing, China).
These constructs were named pGL3-WT1, and pGL3-
WT1 mut. For reporter assay, cells were plated onto
24-well plates and transfected with 100 ng of pGL3-
WT1, pGL3-WT1-mut, respectively, using Lipofecta-
mine 2000 (Invitrogen Corp, CA, and USA). A Renilla
luciferase vector pRL-SV40 (5 ng) was also co-transfected
to normalize the differences in transfection efficiency.
After transfection for 48 h, cells were harvested and
assayed with the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI) according to the manufacturer’s
instructions. Transfection was repeated three times in
triplicate.
Data analysis
All experiments were independently repeated at least
triplicate. Data were expressed as mean ± SD. Chi-square
tests was used to evaluate statistical differences in demo-
graphic and clinical characteristics in HCC patients. Dif-
ferences between two independent groups including
clinical samples and in vitro study were tested with the
student t test. Pearson correlation was applied to analyze
the correlation between WT1 and WT1-AS. All statis-
tical analyses were carried out using SPSS version 18.0
and presented with Graphpad prism software. Kaplan-
Meier survival curves were plotted and log rank test was
done. The significance of various variables for survival
was analyzed by Cox proportional hazards model in a
multivariate analysis. The results were considered to be
statistically significant at P < 0.05.
Results
WT1-AS expression correlated negatively with WT1
expression in HCC tumors
In order to investigate whether changes in WT1-AS expres-
sion are associated with HCC, we quantified the expression
of WT1-AS in tumor tissues and the corresponding adja-
cent tissues. WT1-AS expression was significantly reduced
in tumor tissue compared to normal tissues (Fig. 1a),
indicating that WT1-AS is involved in HCC. We also
confirmed the up-regulation of WT1 expression in HCC
tumors (Fig. 1b, c).
The correlation of WT1-AS and WT1 expression and
the ability of WT1-AS to regulate WT1 have not been
investigated so far. To address this, we analyzed the cor-
relation of WT1-AS and WT1 expression using Pearson
correlation analysis. We confirmed an inverse correl-
ation between WT1-AS and WT1 expression (Fig. 1d).
The Coding Protein Calculator (http://cpc.cbi.pku.edu.
cn/) was used to examine the protein coding ability of
WT1-AS. Comping with MEG3, WT1-AS was shown to
be a non-coding RNA (Fig. 1e).
WT1-AS is a reliable predictor of HCC prognosis
The expression of WT1-AS in HCC and adjacent normal
liver tissues was re-evaluated. Evaluation of the 95 % CI in
the adjacent normal tissues group indicated a threshold of
−0.1398 for discriminating normal tissue from tumor
tissue. Therefore, we divided our 65 patients into two
groups; the WT1-AShigh group (34 cases) and the WT1-
ASlow group (31 cases). The 5-year survival rate in the
WT1-AShigh group was significantly higher than the
WT1-ASlow group (P = 0.0018, 95 % CI). WT1-AS might
be a reliable indicator for the prognosis of HCC (Fig. 1f).
WT1-AS suppresses proliferation and promotes apoptosis
in human HCC cells
WT1 and WT1-AS expression was measured in the human
HCC cell lines 97H, 97 L, HepG2, SMCC-7721, SNU-423
and Huh7. As a control, expression was also measured in
the normal human hepatocyte cell line L02. WT1-AS ex-
pression was significantly lower in the HCC cell lines com-
pared to L02 cells (Fig. 2a). In contrast, WT1 expression
was significantly higher in the HCC cell lines compared to
L02 cells (Fig. 2b). We performed further functional investi-
gations in the HepG2 and L02 cell lines.
We manipulated WT1-AS and WT1 expression in L02
and HepG2 cells by overexpression and shRNA and
investigated the reciprocal effect on protein and mRNA
expression by western-blot and real-time PCR (Fig. 2c).
Downregulation of WT1-AS expression by shRNA in
L02 cells did not affect WT1 transcription, whereas
overexpression of WT1-AS in HepG2 cells significantly
down-regulated the level of WT1 mRNA, suggesting
that WT1-AS might downregulate WT1 expression in
HCC through a direct interaction rather than by block-
ing transcription.
Overexpression of WT1 significantly increased the pro-
liferation of L02 cells (L02-WT1), but the downregulation
of WT1-AS had no influence on the proliferation of L02
cells (L02-shT1-AS). In contrast, the proliferation of
HepG2 cells was significantly decreased by the downregu-
lation of WT1 (HepG2 shWT1) or the overexpression of
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WT1-AS (HepG2 WT1-AS). Overexpressing WT1 in
HepG2 WT1-AS cells was sufficient to reverse the effect
of WT1-AS on HepG2 cell proliferation (Fig. 2d, e).
We investigated the effect of WT1 and WT1-AS on
cell apoptosis using a H2O2 induced model (Fig. 2f, g).
The rate of apoptosis decreased significantly in L02 cells
when WT1 was overexpressed. Interestingly, WT-AS1
knockdown had no effect on apoptosis in L02 cells. In
HepG2 cells, apoptosis increased significantly when
WT1 was knocked down or when WT1-AS was
Fig. 1 WT1-AS was down-regulated with a high correlation with WT1 in HCC acting as an ideal indicator for good prognosis of human HCC.
a Down-regulated level of WT1-AS in HCC tissues compared with the corresponding adjacent tissues. b Up-regulated level of WT1 mRNA in
HCC. c Protein expression level of WT1 in HCC tissues. d Data were analyzed using the Pearson correlation analysis with natural log transformed
expression levels. The result showed that there was an inverse correlation between WT1 and WT1-AS expression levels (P = 0.002, R2 = 0.76).
e Coding Protein Calculator (http://www.lncipedia.org/) was employed to examine the protein coding ability of WT1-AS. MEG3 was regarded as a
positive control. f Expression of WT1-AS in human HCC and adjacent normal tissues. The threshold discriminating normal from elevated systemic
levels was obtained using 95 % CI in the healthy controls. g The Kaplan–Meier curve for the overall survival of patients was presented by using
WT1-AS expression
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overexpressed. The greater increase in apoptosis was in-
duced by WT1 knock-down and was rescued by re-
transfection of WT1.
WT1-AS controls WT1 expression through a reciprocal
feedback loop
We used a bioinformatics approach to further explore
the relationship between WT1-AS and WT1. FISH
assays were performed to investigate the subcellular
localization of WT1-AS and WT1 in HCC cell lines.
The transcript of WT1-AS was located primarily in the
nucleus of Huh7 and HepG2 cells (Fig. 3a). While ana-
lyzing a 2-kb region upstream of the transcription start
site of WT1 using the UCSC genome browser, we
observed that WT1-AS may bind to the WT1 TATA
region. The WT1-AS binding site sequences in the
promoter region of WT1 are presented in Fig. 3b, c. We
observed a reduction of wild-type WT1 luciferase activ-
ity when WT1-AS was overexpressed in HepG2 and
Huh7 cells (P < 0.001), but not when the WT1-AS bind-
ing sequences were mutated (Fig. 3d, e). These results
suggest that WT1-AS binds to a specific promoter region
of WT1 to inhibit transcription.
WT1-AS negatively regulates WT1-mediated resistance to
chemotherapy through JAK2/STAT3 and MAPK signaling
HCC is commonly treated by chemotherapeutic drugs
that inhibit apoptosis [16]. To investigate the association
of WT1-AS expression with chemotherapeutic drug
resistance, two HCC cell lines with a low expression of
WT1-AS and a high expression of WT1 were treated
with the commonly used chemotherapeutic drug
Fig. 2 Apoptosis promoting and proliferation inhibiting effect of WT1-AS by targeting WT1. a and b Expression of WT1-As and WT1 determined
in various human HCC cell lines indicated in the figure. c Detection of WT1-AS and WT1 expression by real-time PCR after transfection (Upper
panel). WT1 expression by western-blot in L02 and HepG2 cells treated with WT1-AS (lower panel). d and e Proliferation curve exampled by EdU
assay for L02 and HepG2 cells treated with various conditions. f and g Cell apoptosis determined detected by PI-Annexin V staining assay for
L02 and HepG2 cell treated with various condition indicated in the figure. All data presented as mean ± SD, *, P < 0.05, **, P < 0.01 by unpaired
Student’s t test
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doxorubicin (DOX). The expression of WT1 increased
gradually with the concentration of DOX (25 ng/mL to
200 ng/mL) in 97H and HepG2 cells. The expression of
WT1-AS also increased significantly with the treatment
of 25 ng/mL DOX to 50 ng/ml DOX, but no further
increase of WT1-AS expression was observed with the
treatment of higher DOX concentrations (Fig. 4a, b), in
agreement with previous findings [10].
The IC50 of DOX was increased by WT1-AS overexpres-
sion and decreased by WT1-AS knock-down in 97H and
HepG2 cell, suggesting that WT1-AS enhances DOX func-
tion. Indeed, overexpressing WT1-AS in 97H and HepG2
cells significantly increased the induction of apoptosis by a
moderate 75 ng/mL dose of DOX. The same effect was
observed when WT1 expression was knocked down in
97H and HepG2 cells. These findings suggested that WT1-
AS may regulate DOX-mediated apoptosis by targeting
WT1. To explore this, we measured the expression of
apoptosis related proteins in HCC cells treated with DOX
(Fig. 4c). The expression of the apoptosis marker caspase 3
subunit p17 increased in all groups treated with DOX and
this increase was significantly higher when WT1-AS was
overexpressed or WT1 was downregulated. We also de-
tected a reduced expression of MDR1, which encodes the
multidrug resistance protein P-glycoprotein, when WT1
was downregulated (Fig. 4d).
WT-1 regulates the oncogenicity of leukemia cells by
activating JAK/STAT3 and MAPK signaling [17, 18],
therefore we explored the role of JAK/STAT3 and MAPK
signaling in the WT1-mediated resistance to DOX.
Fig. 3 WT1-AS reciprocally control WT1 expression through a feedback loop. a Subcellular localization investigation by FISH indicated that the transcript
for WT1-AS was located mainly in the nucleus of Huh7 and HepG2 cell lines, the upper panel indicated Huh7 while the down panel indicated HepG2. DAPI
was used as the control for labeling the nucleus. b Sequences of the binding site for WT1-AS in the promoter region of WT1 and the WT1 promoter and a
mutant sequence were cloned for further experiments. Wild type presented in blue while mutant type in red. c Bioinformatics predicted the binding site
between the WT1-AS with WT1. d, e Cells were co-transfected with WT1-AS plasmid or control, Renilla luciferase vector pRL-SV40 and WT1 promoter (wild
type and mutant type). Both firefly and Renilla luciferase activities were measured in the same sample. Firefly luciferase signals were normalized with Renilla
luciferase signals. Cells treated with controls plasmid were normalized to 100 %. Panel d presented HepG2 cell line while panel e presented Huh7. All data
presented as mean ± SD, * indicated P< 0.05 by unpaired Student’s t test
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Upregulation of WT1 expression by DOX treatment
activated MAPK and STAT3 signaling in HepG2 and 97H
cells, as indicated by an increased phosphorylation of
STAT3 and MAPK and the increased expression of down-
stream targets such as BCL-2 (Fig. 4e). Antagonists of
MAPK (SB203580) and STAT3 (AG490) signaling were
used to confirm the effect of WT1 specifically on these
pathways. AG490 and SB203580 treatment significantly
increased the apoptosis rate in 97H and HepG2 cells, es-
pecially when used in combination. Overexpression of
Fig. 4 WT1-AS was a negative regulator for chemo-resistance though JAK2/STAT3 and MAPK signaling. a, b Expression of WT1-AS and WT1 determined
by real-time PCR in HepG2 and 97H cells treated with doxorubicin (DOX) at concentration of 25, 50, 100, 200 ng/m. c Cell apoptosis determined detected
by PI-Annexin V staining assay for 97H and HepG2 treated with either WT1-AS and shRNA targeting WT1. d Determination of DOX IC50 on 97H and
HepG2 cells treated as indicated in the figure (upper panel). Expression of WT1, Caspase 3, and MDR1 in both 97H and HepG2 cells transfected with either
WT1-AS and shRNA targeting WT1 and further treated with or without DOX at concentration of 75 ng/mL (lower panel). e Expression of WT1, p-STAT3,
STAT3, p-MAPK, MAPK and Bcl-2 in 97H, HepG2 as well as their siWT1 treated cells treated with various concentration of DOX indicated in the figure. f Cell
apoptosis determined detected by PI-Annexin V staining assay for 97H and HepG2 cell treated with various conditions indicated in the figure. All data
presented as mean ± sd, N.S., No significance, ** indicated P< 0.01 by unpaired Student’s t test
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WT1 was not able to rescue apoptosis when either STAT3
or MAPK signaling was blocked (Fig. 4f). Our findings
provide evidence that WT1 induces resistance to DOX
through JAK2/STAT3 and MAPK signaling.
Discussion
WT1 encodes a zinc-finger transcription factor and was
first described as a tumor suppressor gene in the pediatric
kidney cancer, Wilms’ tumor. In normal tissues, WT1 is
an important regulator of cell growth and development
[19, 20]. It controls embryogenesis and influences the
correct formation of many organs and tissues [21, 22].
However, the role of WT1 in cancer is complicated, with
conflicting reports as to whether it has a tumor suppressive
or oncogenic function [23, 24]. In this study we revealed an
oncogenic role for WT1, promoting proliferation and
inhibiting apoptosis in HCC cells. WT1 also promoted the
resistance of HCC cells to a chemotherapeutic drug, in
agreement with previous findings, possibly by activating
JAK2/STAT3 and MAPK signaling [10].
We have demonstrated that WT1-AS regulates expres-
sion of WT1 in HCC tumors, but not in normal tissue.
WT1-AS has previously been implicated in tumorigenesis
by interacting with WT1 [25, 26]. therefore our findings
imply that WT1-AS can inhibit the growth of HCC tu-
mors, possibly by reversing the oncogenic effect of WT1
on HCC cell proliferation and apoptosis. We have also
provided evidence that WT1-AS can attenuate the resist-
ance of HCC cells to a chemotherapeutic drug by influen-
cing the activation of JAK2/STAT3 and MAPK signaling
by WT1. WT1-AS appears to regulate WT1 by binding
directly to its promoter region.
Conclusions
We have demonstrated that high WT1-AS expression is
indicative of a good prognosis for HCC, possibly by
reversing the oncogenic effects of its target WT1.
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